Table of contents


On, 11 December 2001 orphan designation (EU/3/01/074) was granted by the European Commission to PPD Global Ltd., United Kingdom, for halofuginone hydrobromide for the treatment of systemic sclerosis.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in November 2019 on request of the Sponsor.

Key facts

Active substance
Halofuginone hydrobromide
Disease / condition
Treatment of systemic sclerosis
Date of first decision
EU designation number

Sponsor's contact details

PPD Global Ltd
Granta Park
Great Abington, Cambridge
Cambridgeshire CB1 6GQ
United Kingdom
Telephone: +44 1223 374 450
Telefax: +44 1223 374 137

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating